Overview

Idera’s drug discovery and development pipeline includes drug candidates with broad potential applications in autoimmune and inflammatory diseases, oncology, respiratory diseases, and for use as vaccine adjuvants.

We seek to advance certain applications through collaborations with pharmaceutical companies. Idera has entered into a collaboration with Merck & Co. for the use of TLR7, 8, and 9 agonists as vaccine adjuvants.

Idera welcomes opportunities for collaborations that would apply our technology in additional areas of unmet medical needs with academic or industry collaborators who bring complementary expertise and experience. If you have an interest in a potential collaboration with Idera, please contact us at: bd@iderapharma.com.